Sugi Predict

Sugi Predict / Compounds / SCHEMBL26119

SCHEMBL26119

SCHEMBL26119

Nc1ccc2c(c1)C(=O)NC(CCCl)O2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.64
▸ MAPK1 P28482 2/20 0.32
▸ POLB P06746 2/20 0.32
▸ ALDH1A1 P00352 4/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ NPC1 O15118 2/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ TP53 P04637 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ CA12 O43570 1/20 0.30
▸ CA9 Q16790 1/20 0.30
▸ PTPRC P08575 2/20 0.30
▸ MEN1 O00255 2/20 0.30
▸ KMT2A Q03164 2/20 0.30
▸ APAF1 O14727 1/20 0.30
▸ TDP2 O95551 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28520053 0.85 PARP1 (0.46) PARP1MAPK1ALDH1A1KDM4EHSD17B10
SCHEMBL29634282 0.85 PARP1 (0.46) PARP1MAPK1ALDH1A1KDM4EHSD17B10
SCHEMBL29634216 0.84 PARP1 (0.43) PARP1MAPK1POLBALDH1A1KDM4E
SCHEMBL28738398 0.84 PARP1 (0.43) PARP1MAPK1POLBALDH1A1KDM4E
SCHEMBL29634337 0.83 PARP1 (0.43) PARP1ALDH1A1KDM4EHSD17B10MEN1
SCHEMBL28532501 0.83 PARP1 (0.43) PARP1ALDH1A1KDM4EHSD17B10MEN1
SCHEMBL28531562 0.82 PARP1 (0.43) PARP1MEN1KMT2A
SCHEMBL29634185 0.82 PARP1 (0.43) PARP1MEN1KMT2A
SCHEMBL11339213 0.78 PARP1 (0.37) PARP1MAPK1POLBALDH1A1KDM4E
SCHEMBL28523387 0.75 ALDH1A1 (0.34) PARP1MAPK1POLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1044 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285282-A1 OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT OCULAR THERAPEUTIX INC (US) 2023-09-14 — — US claimed
EP-4236943-A1 OCULAR IMPLANT CONTAINING AN ACTIVE AGENT Ocular Therapeutix, Inc. (US) 2023-09-06 — — EP claimed
WO-2022093818-A1 OCULAR IMPLANT CONTAINING AN ACTIVE AGENT OCULAR THERAPEUTIX, INC. (US) 2022-05-05 — — WO claimed
EP-2560634-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS Piramal Enterprises Limited (IN) 2013-02-27 — — EP claimed
US-20120063996-A1 NOVEL NIMESULIDE COMPOSITIONS ELAN PHARMA INTERNATIONAL LTD. 2012-03-15 — — US claimed
WO-2011132171-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 — — WO claimed
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 — — US claimed
US-20090312433-A1 TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT AMGEN INC. 2009-12-17 — — US claimed
US-20090306412-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS ANTIBE THERAPEUTICS INC. (CA) 2009-12-10 — — US claimed
EP-1617816-B1 NANOPARTICULATE MELOXICAN FORMULATIONS ELAN PHARMA INT LTD (IE) 2009-05-13 — — EP claimed
US-20030180357-A1 Pharmaceutical tablet MCNEIL-PPC, INC 2003-09-25 — — US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 — — EP claimed
JP-2003515526-A — — 2003-05-07 — — JP claimed
EP-1252133-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-10-30 — — EP claimed
CN-1356981-A Pharmaceutical compounds NICOX SA (FR) 2002-07-03 — — CN claimed
EP-1192129-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-04-03 — — EP claimed
WO-2001012584-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2001-02-22 — — WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000061549-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 — — WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030180357-A1 Pharmaceutical tablet GYPA, SORD, SRI PARP1 3280/4885MAPK1 4084/4885POLB 4083/4885
US-20090306412-A1 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS HRH4, HRH2, HNMT PARP1 3142/4885MAPK1 3622/4885POLB 3454/4885
US-20120063996-A1 NOVEL NIMESULIDE COMPOSITIONS NIM1K, NIT2, NCL PARP1 3622/4885MAPK1 4591/4885POLB 2723/4885
US-20090312433-A1 TREATMENT OF VR1-ANTAGONIST-INDUCED INCREASE IN BODY TEMPERATURE WITH AN ANTIPYRETIC AGENT VRK1, VIPR1, AVPR1A PARP1 2577/4885MAPK1 738/4885POLB 3826/4885
US-20230285282-A1 OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT ERBB2, BTK, ERBB3 PARP1 4614/4885MAPK1 204/4885POLB 4423/4885
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents NOS2, NOS1, NOS3 PARP1 2547/4885MAPK1 1221/4885POLB 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.